LGM
GPCR icon

Logos Global Management’s Structure Therapeutics GPCR Stock Holding History

Logos Global Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-450,000
Closed -$17.7M – 62
2024
Q2 		$17.7M Hold
450,000
– – 1.42% 19
2024
Q1 		$19.3M Buy
+450,000
New +$19M 1.56% 22

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Logos Global Management's GPCR Position: Q2 2026 in Review

Logos Global Management held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 500,000 shares worth $26.8M. The position accounts for 1.16% of the portfolio, ranked #29.

Logos Global Management first reported a position in GPCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $54.9M in Q3 2024. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Logos Global Management held 500,000 shares of Structure Therapeutics worth $26.8M as of Q2 2026.
  • Logos Global Management left its Structure Therapeutics share count unchanged in Q2 2026.
  • Structure Therapeutics made up 1.16% of Logos Global Management's portfolio in Q2 2026, its #29 holding.
  • Logos Global Management first reported a position in Structure Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Logos Global Management's Structure Therapeutics position peaked at $54.9M in Q3 2024.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.